NEW
YORK, Dec. 1, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, today announced
that members of the Company's management team will participate in
Canaccord Genuity's New Paradigms and Treatment Approaches in
Mental Health Conference.
Canaccord Genuity New Paradigms and Treatment Approaches in
Mental Health Conference
Format: Panel presentation and
one-on-one investor meetings
Panel Date: Tuesday, December 13,
2022
Panel Time: 11:00 a.m. EST /
8:00 a.m. PST
Location: Virtual
An audio webcast and replay of the panel presentation will be
available on the Investor Resources page of the MindMed
website.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders. Our mission is to
be the global leader in the development and delivery of treatments
that unlock new opportunities to improve patient outcomes. We are
developing a pipeline of innovative drug candidates, with and
without acute perceptual effects, targeting the serotonin,
dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-the-canaccord-genuity-new-paradigms-and-treatment-approaches-in-mental-health-conference-301691169.html
SOURCE Mind Medicine (MindMed), Inc.